On February 1, Roche released its 2016 financial report. As a giant in the medical industry , Roche is a leader in the pharmaceutical and diagnostic industries. According to the newly released annual report, the author will review the development of the Roche Diagnostics business in the past year.

Overall performance

In 2016, Roche Group's sales amounted to 50.6 billion Swiss francs, a 4% increase, and net profit reached 9.7 billion Swiss francs, an increase of 7%. The overall performance was good and reached the expected growth target.

Among them, the pharmaceutical business revenue was 39.1 billion Swiss francs, an increase of 3%. The main growth was from drugs such as Perjeta, Herceptin and Actemra/RoActemra. , including Pegasys, erlotinib (Tarceva) and ranibizumab (Lucentis);

Diagnostic business revenue of 11.5 billion Swiss francs, sales increased by 7%, professional diagnosis is the main source of growth, especially immunodiagnosis;

Continued high investment in research and development, reaching 9.9 billion Swiss francs, accounting for about 20% of total revenue;

Table 1. Roche 2016 Financial Data

(in millions of Swiss francs)

Diagnostic product line

The Roche Diagnostics business is divided into four sections, Central Laboratory and POC Diagnostics (formerly known as Professional Diagnostics), Diabetes Care, Molecular Diagnostics and Tissue Diagnostics (Tissue). Diagnostics).

The central laboratory and POC diagnosis were indispensable, with a growth of 9%, of which immunodiagnosis and biochemical diagnosis increased by 13% and 6%, respectively;

The diabetes management business has dropped 4% due to the price reduction pressure in the US market. The diabetes management business has continued to decline in the past two years;

The molecular diagnostics business grew by 7%, with microbiological diagnostic sales increasing by 9% and HPV (human papillomavirus) screening increasing by 8%. Thanks to winning the bid in many countries, the blood screening business also grew by 5%;

The growth rate of tissue diagnosis reached 14%, of which the accompanying diagnosis business increased by 46%.

Table 2. Diagnose financial data for each segment of the business

(in millions of Swiss francs)

The best-selling products in the diagnostic business are shown below:

figure 1. Roche Diagnostics' best-selling product

(in millions of Swiss francs)

As can be seen from the best-selling varieties, Roche's best-selling products are concentrated in central laboratories, including immunological, biochemical, microbiological and histopathological diagnoses, while sales of diabetes monitoring products have declined.

Foot Spa Massager

Foot Spa Massager,Bath Foot Massager Machine,Foot Spa Bath,Bath Foot Massager With Bubble

Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootspabath.com